News & Events

Learn about what's new with CMC Biologics

CPhI Japan 2017, April 19 - 21, Tokyo, Japan

BIO Korea 2017, April 12 - 14, Seoul, South Korea

BIO-Europe Spring 2017, March 20 - 22, Barcelona, Spain

CMC Biologics and Genexine Announce Manufacturing Agreement for Genexine's Human Growth Hormone Drug, GX-H9

DCAT 2017, March 20 - 23, New York, NY

CMC Biologics Enters into Manufacturing Agreement with CytoDyn

BioProcess International West 2017, February 28 - March 2, San Francisco, CA - Booth #410

Cell Culture & Downstream World Congress 2017, February 21 - 22 - Munich, Germany

World ADC 2017, February 20 - 22, Berlin, Germany - Booth #4

Biotech Showcase, January 9-13

AGC Asahi Glass Signs Agreement to Acquire CMC Biologics

Achieving Continuous Downstream Bioprocessing

European Antibody Congress, November 14 - 16, Booth #9

BIO Europe, November 7 - 9, Booth #43

CMC Biologics Participates in Denmark State Visit to Korea

BioProduction , October 19 - 20, Booth #29

CMC Biologics and IDT Biologika Announce the Addition of Cerbios-Pharma and Oncotec Pharma to their Strategic Collaboration

Biotech Week Boston, 2016

BioProcess International, October 4 - 7, Booth #1035

CPhI Worldwide, October 4 - 6, Barcelona, Spain

Quality by Design: Transforming 21st Century Pharmaceutical Manufacturing

CMC Biologics Cleared for Commercial Manufacture of CSL Behring's FDA-Approved AFSTYLA®

CMC Biologics Expands GMP Manufacturing Capacity in Europe

Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst's Next-Generation Factor VIIa Product CB 813d

BIO International, June 6 - 9, Booth #5868

Life Science Innovation Northwest, June 1 -2, Booth #216

Scale Down Models: An Indispensable Tool to Biopharmaceutical Process Development

Outsourced Pharma EAST, April 20 - 21

CMC Biologics Recognized as a Leader in Contract Development and Manufacturing by Customers and the Biopharmaceutical Industry

Bio Europe Spring, April 4-6 - Booth #4

BioProcess International, April 11 - 14, Booth #67

CMC Biologics and IDT Biologika Announce a Strategic Collaboration to Manufacture Antibody Drug Conjugates

Growing Through Innovation : The new chief exec talks about industry trends and growth plans with Contract Pharma

Advancing Biologics Development and Manufacturing

Setting a Path for Growth

Agreement with Immunocore for Process Transfer, Scale-up and Commercial-scale manufacturing of IMCgp100

CMC Biologics Announces Appointment of New CEO

Governor Inslee’s Director of Life Science and Global Health Development, Maura Little, Presides Over CMC Biologics’ Ribbon Cutting Ceremony Commemorating the Bioreactor 6Pack™ Manufacturing Facility

CMC Biologics Enters into Agreement with the PATH Malaria Vaccine Initiative for Accelerated Development and Manufacturing of Monoclonal Antibodies

CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave’s Orbitopathy

CMC Biologics Expands GMP Manufacturing Capacity in the United States

CMC Biologics Expands European GMP Manufacturing Capacity

CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe

CMC Biologics in Commercial Supply Agreement with Emergent BioSolutions for FDA-Approved IXINITY®

CMC Biologics Recognized for Quality and Reliability at the 2015 CMO Leadership Awards Ceremony

Serendex Pharmaceuticals and CMC Biologics Enter Exclusive Agreement on Factor VIIa

CMC Biologics and OncoSynergy Enter into an Agreement for Accelerated Process Development and GMP Manufacture of an Investigational Drug to Combat Ebola

Joseph Wypych, 20-year Biopharmaceutical Executive, Joins CMC Biologics as General Manager, Seattle Facility

CMC Biologics and Zymeworks Enter into Agreement for Process Development and Clinical Manufacture of Bi-Specific Antibody Product Candidate

CMC Biologics Enters into Commercial Supply Agreement with Portola Pharmaceuticals for Manufacturing of First-In-Class Factor Xa Inhibitor Antidote Andexanet Alfa

CMC Biologics and MacroGenics Enter into Process Validation and Clinical Manufacturing Agreement for Commercialization of Next-Generation Oncology Product Candidate

CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate

CMC Biologics Wins 2014 CMO Leadership Awards for Innovation, Quality and Reliability

Jesper Bramming, former A.P. Moller Executive, Joins the CMC Biologics  Executive Management Team as Chief Financial Officer

CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials

CMC Biologics Enters into Agreement with the University of Copenhagen for Development and Clinical Manufacture of Placental Malaria Vaccine

CMC Biologics Achieves Authorization for cGMP Commercial Manufacturing by the Danish Medicines Agency

Quality by Design: A CMO’s Perspective on Gaining Knowledge Faster and Better

CMC Biologics and RuiYi Enter into Agreement to Develop Anti-IL-6 mAb

CMC Biologics Wins 2013 CMO Leadership Award for Innovation, Quality and Reliability

CMC Biologics Establishes Commercial Presence In Japan through Strategic Agreement with Innomedica

CMC Biologics Announces Mark W. Sawicki as Global Vice President, Business Development

CMC Biologics Announces New General Manager of Copenhagen Facility

CMC Biologics Acquires XOMA’s Bay Area Manufacturing Facility – Fierce Biotech

CMC Biologics Buys Bay Area Manufacturing Facility – Northwest Innovation

CMC Biologics Snaps Up Biotech Manufacturing Plant from XOMA — Xconomy

CMC Biologics Acquires XOMA’s Bay Area Manufacturing Facility; Term Not Disclose – Benzinga

CMC Biologics in BioSpace News

CMC Biologics Acquires XOMA’s Bay Area Manufacturing Facility

CMC Biologics to Buy XOMA’s Manufacturing Facility – San Francisco Business Times

CMC Biologics Featured in July 2012 Contract Pharma: “A Chat with CMC Biologics at BIO 2012” by Mak Jawadekar, Contributing Editor

CMC Biologics Achieves Successful Pre-Approval European GMP INspection by MHRA for Commercial Manufacturing

CMC Biologics Honored as Finalist for Washington’s Manufacturing Company of the Year Award

CMC Biologics Highlights Technical Acumen at Numerous Conferences

CMC Biologics, Thermo Fisher Scientific, Applikon Biotechnology and BioProcess International Highlight Industry

CMC Biologics Announces Agreement with Daiichi Sankyo to Develop and Manufacture Antibodies

Bothell’s CMC Biologics Expands Facility to Develop Drugs for Clinical Trials – The Herald

Director of Commerce, Rogers Weed, Presided Over Ribbon Cutting Ceremony Celebrating Opening of Expanded Manufacturing Facility at CMC Biologics

CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001

CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility

CMC Biologics Announces Appointment of New CFO

CMC Biologics Expands its Production Facility and Rebrands it’s Corporate Identity

CMC Biologics Announces Appointment of New CEO – Claes Glassell, Former CEO of Cerus Corporation to Take Helm

Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein

CMC Biologics Completes First Stage of Expansion with Addition of Single-use Facility

ProtAffin AG Signs Manufacturing Contract for PA401 with CMC Biologics A/S

CMC ICOS Mounts Comeback, Resumes Hiring, After Pausing During the Downturn – Xconomy